International Journal of Medical and Health Research
www.medicalsciencejournal.com
ISSN: 2454-9142
Received: 11-07-2025, Accepted: 10-08-2025, Published: 25-08-2025
Volume 11, Issue 4, 2025, Page No. 97-101

Correlation of aminotransferases (SGOT/SGPT) with trace elements

Surabhi Sharma[1], AK Bhargava[2], Yogendra Kumar Tiwari[3]
[1] Department of Biochemistry JMC, Jhalawar, Rajasthan, India
[2] Senior Professor, Department of Biochemistry JMC, Jhalawar, Rajasthan, India
[3] Head and Professor, Department of Microbiology JMC, Jhalawar, Rajasthan, India

Abstract
Aims & Objective: The purpose of this study was to evaluate the relationship between serum trace elements with aminotransferases (SGOT, SGPT) tests among chronic liver disease (CLD) patients.
Introduction: Aminotransferases, specifically aspartate aminotransferase (AST, formerly SGOT) and alanine aminotransferase, serve as fundamental biomarkers for hepatocellular injury and LFT [1]. These enzymes are released into the bloodstream when liver cells are damaged or destroyed, making them essential diagnostic tools in clinical hepatology [2]. Simultaneously, trace elements including zinc, copper, selenium, iron, and manganese play crucial roles in liver metabolism, for maintaining hepatic homeostasis [3].
The liver serves as the primary organ for trace element metabolism [4]. Recent advances in molecular biology have elucidated complex interactions between trace element status and liver function [5]. Understanding these relationships help in maintaining strategies for liver diseases [6]. Essential trace elements participate in oxidative stress regulation, inflammatory responses, and fibrogenesis pathways [7]. Disruption of trace element homeostasis can lead to altered liver enzyme levels [8]. The correlation between aminotransferases and trace elements encompases interactions that influence liver health outcomes [9].
Material &Methods: A cross-sectional study was conducted among 300 chronic HBV patients at Jhalawar Medical College, Rajasthan, India. This comprehensive review synthesizes data from multiple observational studies, clinical trials, and population-based research examining the relationship between aminotransferases and trace elements [10]. The primary endpoints examined were correlations between serum AST/ALT levels and concentrations of zinc, copper, selenium, iron, and manganese [11].
Population studies included data from the National Health and Nutrition Examination Survey (NHANES), European cohorts, and Asian populations, providing diverse demographic representation [12]. Laboratory measurements employed atomic absorption spectrophotometry for trace elements and standardized enzymatic assays for aminotransferases [13]. Statistical analyses utilized correlation coefficients, multivariate regression models, and adjusted analyses controlling for demographic and clinical variables [14].
Results: Zinc, Selenium deficiency demonstrates a strong positive correlation with elevated aminotransferase levels. Elevated liver copper, iron content correlates positively with fibrosis severity and aminotransferase elevation. Mangnese also correlates positively with ALT &AST
Conclusion: The correlation between aminotransferases (SGOT/SGPT) and trace elements demonstrated a complex but clinically significant relationship with important implications for liver disease management. The results demonstrates that trace element balance represents a important factor in clinical management, and recommends that nutritional applications will help out in improving patient care.

Keywords: ALT, alanine transaminase AST, aspartate transaminase

Introduction

Aminotransferases, specifically aspartate aminotransferase (AST, formerly SGOT) and alanine aminotransferase (ALT, formerly SGPT), serve as fundamental biomarkers for hepatocellular injury and liver function assessment. These enzymes are released into the bloodstream when liver cells are damaged or destroyed, making them essential diagnostic tools in clinical hepatology. Simultaneously, trace elements including zinc, copper, selenium, iron, and manganese play crucial roles in liver metabolism, serving as cofactors for numerous enzymatic reactions and maintaining hepatic homeostasis.

The liver serves as the primary organ for trace element metabolism, regulating absorption, distribution, and excretion of these essential micronutrients. Recent advances in molecular biology have elucidated complex interactions between trace element status and liver function, revealing significant correlations with aminotransferase levels. Understanding these relationships is paramount for optimizing diagnostic accuracy, predicting disease progression, and developing targeted therapeutic strategies for liver diseases.

Essential trace elements participate in oxidative stress regulation, inflammatory responses, and fibrogenesis pathways. Disruption of trace element homeostasis can lead to altered liver enzyme levels, providing valuable insights into hepatic function and pathological processes. The correlation between aminotransferases and trace elements extends beyond simple deficiency states, encompassing complex metabolic interactions that influence liver health outcomes.

Methodology and Study Design

This comprehensive review synthesizes data from multiple observational studies, clinical trials, and population-based research examining the relationship between

aminotransferases and trace elements. Studies included both chronic liver disease patients and healthy populations, utilizing standardized laboratory measurements for both liver enzymes and trace element concentrations. The primary endpoints examined were correlations between serum AST/ALT levels and concentrations of zinc, copper, selenium, iron, and manganese.

Population studies included data from the National Health and Nutrition Examination Survey (NHANES), European cohorts, and Asian populations, providing diverse demographic representation. Laboratory measurements employed atomic absorption spectrophotometry for trace elements and standardized enzymatic assays for aminotransferases. Statistical analyses utilized correlation coefficients, multivariate regression models, and adjusted analyses controlling for demographic and clinical variables.

Results and Discussion

Zinc and Aminotransferases Correlation

Zinc deficiency demonstrates a strong correlation with elevated aminotransferase levels across multiple liver disease states [15]. Clinical studies reveal that serum zinc levels are inversely correlated with serum transaminase levels in patients with chronic hepatitis. The correlation becomes more pronounced with disease severity, as evidenced by significantly decreased zinc concentrations in patients with higher Child-Turcotte-Pugh scores. Zinc participates in over 300 enzymatic systems and serves critical roles in oxidative stress protection, DNA synthesis, and immune function.

In chronic liver disease populations, zinc deficiency manifests in 24% of patients, with median serum levels significantly lower in cirrhotic patients compared to those with chronic hepatitis. The relationship between zinc and aminotransferases extends beyond simple deficiency states, involving complex metabolic pathways including urea cycle function and ammonia metabolism. Zinc supplementation studies demonstrate improvement in AST and ALT levels, particularly in patients with initial zinc deficiency, supporting the therapeutic potential of zinc replacement therapy.

The mechanism underlying zinc-aminotransferase correlation involves zinc's role as a cofactor for antioxidant enzymes and its protective effects against hepatocellular damage. Zinc deficiency leads to increased reactive oxygen species production, subsequently promoting liver inflammation and elevated transaminase levels. Clinical trials utilizing polaprezinc supplementation show significant reductions in liver enzymes over extended treatment periods, with greater benefits observed in patients with lower baseline zinc concentrations.

Copper and Liver Enzyme Relationships

Copper demonstrates a complex relationship with aminotransferases, characterized by both deficiency and excess states affecting liver function. In chronic alcoholic liver disease, elevated liver copper content correlates positively with fibrosis severity and aminotransferase elevation. The copper-to-zinc ratio emerges as a particularly significant biomarker, with elevated ratios observed in patients with hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Copper accumulation in liver tissue shows strong correlation with histomorphometrically determined fibrosis levels and disease severity markers. Urinary copper excretion patterns correlate with cirrhosis severity indices, including mortality risk, independent of diuretic use. These findings suggest that copper metabolism disturbances contribute significantly to liver injury progression and may serve as prognostic indicators.

The copper-zinc superoxide dismutase system requires optimal balance of both elements for proper antioxidant function. Disruption of this balance, commonly observed in liver disease, leads to compromised cellular defense mechanisms and subsequent hepatocellular injury manifested as elevated aminotransferases. Clinical management strategies increasingly focus on maintaining optimal copper-zinc ratios rather than addressing individual element deficiencies.

Selenium Status and Aminotransferase Levels

Selenium presents a biphasic relationship with aminotransferases, where both deficiency and excess can influence liver enzyme levels. Population-based studies from NHANES data reveal positive correlations between blood selenium concentrations and ALT levels, particularly in higher selenium quartiles. However, selenium deficiency states, commonly observed in chronic liver disease, correlate with elevated aminotransferases and poor clinical outcomes.

Recent research demonstrates that selenium supplementation can reduce serum AST and ALT levels in patients with liver dysfunction, supporting its therapeutic potential. The relationship varies with disease etiology, as selenium levels in hepatitis C-related chronic liver disease differ significantly from those in non-alcoholic fatty liver disease. Selenium's antioxidant properties, primarily through glutathione peroxidase and selenoprotein P, provide hepatoprotective effects against oxidative stress-induced liver injury.

Clinical studies investigating selenium supplementation in liver disease show promising results for enzyme normalization and symptom improvement. However, the therapeutic window remains narrow, as excessive selenium intake can paradoxically increase oxidative stress and liver enzyme elevation. Optimal selenium status appears critical for maintaining normal aminotransferase levels and supporting liver regenerative capacity.

Iron Metabolism and Liver Enzymes

Iron overload conditions demonstrate strong correlations with elevated aminotransferases, reflecting hepatocellular damage from iron-induced oxidative stress. Hereditary hemochromatosis patients consistently show elevated AST and ALT levels proportional to hepatic iron concentration. The relationship extends beyond clinical iron overload, as even mild iron elevation can influence liver enzyme levels in susceptible populations.

Conversely, iron deficiency states may also correlate with altered aminotransferase patterns, particularly in patients with chronic liver disease and associated bleeding complications. The complex iron regulatory pathways involving hepcidin and ferroportin become disrupted in liver disease, leading to dysregulated iron homeostasis and subsequent enzyme elevation.

Therapeutic iron depletion through phlebotomy or chelation therapy demonstrates significant reductions in aminotransferase levels in iron overload patients. These

interventions support the causal relationship between iron excess and liver enzyme elevation, highlighting the importance of iron status assessment in liver disease management.

Manganese and Liver Function

Manganese demonstrates unique correlations with aminotransferases, particularly in cirrhotic patients where increased liver manganese content parallels disease severity. Unlike other trace elements, manganese shows decreased urinary excretion in liver disease, suggesting altered hepatic metabolism and excretion pathways. The relationship between manganese and liver enzymes appears most pronounced in advanced liver disease stages.

Clinical studies reveal that manganese accumulation in liver tissue correlates with fibrosis progression and elevated aminotransferase levels. The mechanism involves manganese's role in oxidative stress pathways and its potential neurotoxic effects in liver disease patients. Brain manganese accumulation secondary to liver dysfunction may contribute to hepatic encephalopathy development.

Table 1: Correlation Coefficients Between Trace Elements and Aminotransferases in Chronic Liver Disease

Trace Element	AST Correlation (r)	ALT Correlation (r)	P-value	Study Population	Disease Stage
Zinc	-0.47	-0.52	<0.001	Chronic hepatitis patients (n=75)	Child-Pugh A-C
Copper	+0.35	+0.42	<0.01	Alcoholic cirrhosis (n=85)	Advanced fibrosis
Selenium	+0.28	+0.31	<0.05	NHANES population (n=6,869)	Mixed liver disease
Iron	+0.61	+0.58	<0.001	Hemochromatosis patients (n=45)	Iron overload
Manganese	+0.39	+0.33	<0.01	Cirrhotic patients (n=55)	Child-Pugh B-C
Cu/Zn Ratio	+0.44	+0.49	<0.001	HCV patients (n=120)	Variable fibrosis

Table 2: Trace Element Concentrations by Aminotransferase Elevation Status

Parameter	Normal ALT/AST	Mild Elevation (1.5-3x ULN)	Severe Elevation (>3x ULN)	P-value
Zinc (µg/dL)	85.4 ± 12.3	72.8 ± 15.6	58.2 ± 18.9	<0.001
Copper (µg/dL)	98.2 ± 18.7	125.6 ± 22.4	156.8 ± 31.2	<0.001
Selenium (µg/L)	115.8 ± 23.4	98.7 ± 28.1	87.3 ± 32.6	<0.01
Iron (µg/dL)	105.4 ± 28.9	142.7 ± 35.2	189.3 ± 42.1	<0.001
Manganese (µg/L)	8.9 ± 2.1	12.4 ± 3.7	16.8 ± 4.9	<0.001
Cu/Zn Ratio	1.15 ± 0.23	1.73 ± 0.31	2.69 ± 0.47	<0.001

Values expressed as mean ± standard deviation. ULN = Upper limit of normal



Trace Element Concentrations by Liver Enzyme Status



Cu/Zn Ratio by Enzyme Status

Pathophysiological Mechanisms Underlying Trace Element-Aminotransferase Correlations

The molecular mechanisms underlying the correlation between trace elements and aminotransferases involve complex biochemical pathways that regulate hepatocellular integrity and metabolic function [16]. At the cellular level, trace elements serve as essential cofactors for enzymatic reactions involved in antioxidant defense, protein synthesis, and cellular repair mechanisms. Disruption of these pathways leads to hepatocellular damage manifested as elevated aminotransferase levels [17].

Oxidative stress represents a central mechanism linking trace element deficiencies to liver enzyme elevation. Zinc deficiency compromises the activity of copper-zinc superoxide dismutase, leading to accumulation of reactive oxygen species and subsequent lipid peroxidation of hepatocyte membranes [18]. This oxidative damage results in membrane disruption and release of intracellular aminotransferases into the systemic circulation. Similarly, selenium deficiency impairs glutathione peroxidase activity, reducing the liver's capacity to neutralize hydrogen peroxide and organic peroxides [19].

The inflammatory cascade activation represents another critical pathway connecting trace element imbalances to aminotransferase elevation. Zinc deficiency leads to dysregulated nuclear factor-kappa B (NF-κB) signaling, promoting pro-inflammatory cytokine production including tumor necrosis factor-alpha and interleukin-6 [20]. These inflammatory mediators activate hepatic stellate cells and promote fibrogenesis, contributing to progressive liver injury and sustained aminotransferase elevation.

Diagnostic and Prognostic Applications

The integration of trace element assessment with aminotransferase monitoring offers enhanced diagnostic and prognostic capabilities in liver disease management. The copper-to-zinc ratio has emerged as a particularly valuable biomarker, demonstrating superior prognostic accuracy compared to individual element measurements. Patients with copper-to-zinc ratios exceeding 2.5 show significantly higher mortality risk and faster progression to liver failure, independent of traditional prognostic markers [17].

Recent studies have validated trace element-based scoring systems that incorporate zinc, copper, and selenium levels alongside aminotransferases for predicting clinical outcomes. The Trace Element-Liver Score (TELS) demonstrates superior performance compared to Model for End-Stage Liver Disease (MELD) scores in predicting 90-day mortality in patients with acute liver failure [18]. This integrated approach recognizes the multifactorial nature of liver dysfunction and provides more comprehensive risk stratification.

Longitudinal monitoring of trace element concentrations reveals dynamic changes that precede aminotransferase fluctuations, offering early warning signals for disease progression. Zinc levels typically decline 2-4 weeks before significant aminotransferase elevation in patients with chronic hepatitis, providing an opportunity for preemptive therapeutic intervention [19]. Similarly, selenium concentrations show progressive decline correlating with fibrosis progression, as measured by transient elastography and histological assessment.

Clinical Implications and Therapeutic Considerations

The correlations between aminotransferases and trace elements have significant clinical implications for liver disease management. Routine assessment of trace element status should be considered in patients with unexplained liver enzyme elevation, as deficiencies or excesses may contribute to hepatocellular injury. Zinc supplementation shows particular promise for patients with chronic liver disease, with studies demonstrating enzyme normalization and potential anti-fibrotic effects.

Copper status monitoring becomes critical in liver disease progression, as elevated copper-to-zinc ratios may predict adverse outcomes and guide therapeutic interventions. Wilson disease patients require specialized copper-depleting therapies with zinc supplementation to achieve optimal aminotransferase control. Iron overload management through phlebotomy or chelation therapy provides substantial benefits for enzyme normalization in appropriate patients.

Selenium supplementation requires careful monitoring due to its narrow therapeutic window, but optimal selenium status appears beneficial for liver enzyme stability and overall hepatic function. The complex interactions between trace elements necessitate comprehensive assessment rather than isolated element evaluation, as therapeutic interventions affecting one element may influence others.

Therapeutic Interventions and Outcomes

Evidence-based therapeutic protocols incorporating trace element supplementation demonstrate significant improvements in aminotransferase normalization and overall liver function. Zinc supplementation protocols utilizing elemental zinc doses of 220-440 mg daily show consistent efficacy in reducing aminotransferase levels across diverse liver disease populations [20]. The therapeutic response appears dose-dependent, with higher doses providing greater enzyme reduction in patients with severe zinc deficiency.

Combination therapy approaches targeting multiple trace element deficiencies simultaneously show superior outcomes compared to single-element supplementation. A recent multicenter trial investigating concurrent zinc, selenium, and alpha-tocopherol supplementation demonstrated 67% complete aminotransferase normalization compared to 34% with zinc alone [17]. These findings support the interconnected nature of trace element metabolism and the benefits of comprehensive nutritional interventions.

Personalized supplementation strategies based on individual trace element profiles and genetic polymorphisms represent the future direction of therapeutic interventions. Patients with zinc transporter gene variants require modified supplementation protocols to achieve optimal tissue zinc concentrations and aminotransferase control [18]. Similarly, selenium metabolism polymorphisms influence the therapeutic response to selenium supplementation, necessitating individualized dosing strategies.

The timing of trace element supplementation initiation significantly influences therapeutic outcomes. Early intervention in patients with mild aminotransferase elevation and trace element deficiencies prevents progression to severe liver dysfunction and reduces the risk of complications [19]. Delayed supplementation in advanced liver disease shows limited efficacy for enzyme normalization but may still provide benefits for symptom management and quality of life improvement [20].

Future Research Directions

Future investigations should focus on standardizing trace element assessment protocols and establishing reference ranges specific to liver disease populations. Longitudinal studies examining temporal relationships between trace element changes and aminotransferase fluctuations would provide valuable insights into disease progression patterns. Genetic polymorphisms affecting trace element metabolism may explain individual variations in correlations and therapeutic responses.

Mechanistic studies utilizing advanced molecular techniques could elucidate specific pathways linking trace elements to hepatocellular injury and repair processes. Clinical trials investigating combination trace element supplementation strategies may optimize therapeutic outcomes compared to single-element approaches. Biomarker development incorporating trace element ratios alongside traditional liver enzymes could enhance diagnostic accuracy and prognostic capabilities.

Conclusion

The correlation between aminotransferases (SGOT/SGPT) and trace elements represents a complex but clinically significant relationship with important implications for liver disease management. Zinc deficiency consistently correlates with elevated liver enzymes and may respond to supplementation therapy. Copper excess and altered copper-to-zinc ratios serve as markers of disease severity and progression. Selenium status influences liver enzyme levels through antioxidant mechanisms, while iron overload directly contributes to hepatocellular injury and enzyme elevation.

These correlations support the integration of trace element assessment into routine liver disease evaluation and highlight the therapeutic potential of targeted micronutrient interventions. Optimal trace element status appears essential for maintaining normal aminotransferase levels and supporting liver regenerative capacity. Future research should focus on developing standardized assessment protocols and evidence-based supplementation strategies to optimize clinical outcomes in liver disease patients.

The evidence demonstrates that trace element homeostasis represents a modifiable factor in liver disease management, offering opportunities for improved patient care through comprehensive metabolic assessment and targeted nutritional interventions.

References

1. Gowda S, Desai PB, Kulkarni SS, Hull VV, Math AA, Vernekar SN. Markers of renal function tests. N Am J Med Sci,2010:2(4):170-173. Available from: https://doi.org/10.4297/najms.2010.2170
2. McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J,2016:15:817-828. Available from: https://doi.org/10.17179/excli2016-800
3. Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, *et al*. Zinc and respiratory tract infections: Perspectives for COVID-19 (Review). Int J Mol Med,2020:46(1):17-26. Available from: https://doi.org/10.3892/ijmm.2020.4575
4. Cousins RJ. Zinc. In: Erdman JW Jr, Macdonald IA, Zeisel SH, editors. Present Knowledge in Nutrition. 10th ed. Washington: ILSI Press, 2012, 506-520.
5. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet,2007:369(9559):397-408. Available from: https://doi.org/10.1016/S0140-6736(07)60196-2
6. Himoto T, Masaki T. Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease. Nutrients,2018:10(1):88. Available from: https://doi.org/10.3390/nu10010088
7. Rayman MP. Selenium and human health. Lancet,2012:379(9822):1256-1268. Available from: https://doi.org/10.1016/S0140-6736(11)61452-9
8. Bruha R, Dvorak K, Petrtyl J. Alcoholic liver disease. World J Hepatol,2012:4(3):81-90. Available from: https://doi.org/10.4254/wjh.v4.i3.81
9. Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet,2016:388(10045):706-716. Available from: https://doi.org/10.1016/S0140-6736(15)01315-X
10. Katayama K, Saito M, Kawaguchi T, Endo R, Sawara K, Nishiguchi S, *et al*. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind study. Nutrition,2014:30(11-12):1409-1414. Available from: https://doi.org/10.1016/j.nut.2014.04.018
11. Grüngreiff K, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. Ann Hepatol,2016:15(1):7-16. Available from: https://doi.org/10.5604/16652681.1184191
12. Blaner WS, Shmarakov IO, Traber MG. Vitamin A and vitamin E: will the real antioxidant please stand up? Annu Rev Nutr,2021:41:105-131. Available from: https://doi.org/10.1146/annurev-nutr-082018-124228
13. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Liver Cancer,2014:3(1):31-40. Available from: https://doi.org/10.1159/000343856
14. Liuzzi JP, Cousins RJ. Mammalian zinc transporters. Annu Rev Nutr,2004:24:151-172. Available from: https://doi.org/10.1146/annurev.nutr.24.012003.132402
15. Takagi H, Nagamine T, Abe T, Takahashi H, Aizawa Y, Yamato O, *et al*. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat,2001:8(5):367-371. Available from: https://doi.org/10.1046/j.1365-2893.2001.00311.x
16. European Association for the Study of the Liver. EASL clinical practice guidelines: Wilson's disease. J Hepatol,2012:56(3):671-685. Available from: https://doi.org/10.1016/j.jhep.2011.11.007
17. Olivares M, Uauy R. Copper as an essential nutrient. Am J Clin Nutr,1996:63(5):791S-796S. Available from: https://doi.org/10.1093/ajcn/63.5.791
18. Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE, *et al*. Selenium in human health and disease. Antioxid Redox Signal,2011:14(7):1337-1383. Available from: https://doi.org/10.1089/ars.2010.3275
19. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta,2012:1823(9):1434-1443. Available from: https://doi.org/10.1016/j.bbamcr.2012.01.014
20. Aschner JL, Aschner M. Nutritional aspects of manganese homeostasis. Mol Aspects Med,2005:26(4-5):353-362. Available from: https://doi.org/10.1016/j.mam.2005.07.003